Publicaciones en colaboración con investigadores/as de Hospital Virgen del Camino (17)

2022

  1. Health-related quality of life in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis treated with certolizumab pegol

    Farmacia Hospitalaria, Vol. 46, Núm. 1, pp. 27-30

2021

  1. Mediterranean diet and risk of dementia and alzheimer’s disease in the epic-spain dementia cohort study

    Nutrients, Vol. 13, Núm. 2, pp. 1-19

2020

  1. Incidence of Dementia and Associated Factors in the EPIC-Spain Dementia Cohort

    Journal of Alzheimer's Disease, Vol. 78, Núm. 2, pp. 543-555

2019

  1. Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments

    Expert Review of Gastroenterology and Hepatology, Vol. 13, Núm. 7, pp. 699-708

2018

  1. Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals

    Revista Espanola de Enfermedades Digestivas, Vol. 110, Núm. 10, pp. 621-628

2017

  1. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients

    Expert Review of Gastroenterology and Hepatology, Vol. 11, Núm. 1, pp. 85-93

2016

  1. Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 16, Núm. 2, pp. 285-294

  2. Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis

    Medicina Clinica, Vol. 146, Núm. 2, pp. 61-64

  3. Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence

    Expert Review of Gastroenterology and Hepatology, Vol. 10, Núm. 11, pp. 1289-1303

2015

  1. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C

    Gut, Vol. 64, Núm. 8, pp. 1277-1288

2014

  1. Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: A systematic review of published literature

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 14, Núm. 3, pp. 387-402

2013

  1. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients

    PharmacoEconomics, Vol. 31, Núm. 10, pp. 919-931

  2. Los costes del ictus en España según su etiología. El protocolo del estudio CONOCES

    Neurologia, Vol. 28, Núm. 6, pp. 332-339

2012

  1. Adherencia subóptima al tratamiento en la esclerosis múltiple

    Farmacia Hospitalaria, Vol. 36, Núm. 3, pp. 124-129

2010

  1. Angina de Prinzmetal en paciente tratado con capecitabina: a propsito de un caso

    Farmacia Hospitalaria

2009

  1. Síndrome mielodisplásico. Papel terapéutico de la azacitidina

    Atencion Farmaceutica, Vol. 11, Núm. 3, pp. 151-160

2008

  1. Tratamiento de linfoma difuso de células B mediastínico durante el embarazo

    Farmacia Hospitalaria